Following The Money: Institution’s Growing Stake In Capricor Therapeutics Inc (NASDAQ: CAPR)

Capricor Therapeutics Inc (CAPR) concluded trading on Thursday at a closing price of $9.56, with 4.79 million shares of worth about $45.79 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -51.07% during that period and on May 15, 2025 the price saw a gain of about 24.64%. Currently the company’s common shares owned by public are about 45.68M shares, out of which, 40.12M shares are available for trading.

Stock saw a price change of 37.16% in past 5 days and over the past one month there was a price change of -2.65%. Year-to-date (YTD), CAPR shares are showing a performance of -30.72% which increased to 75.74% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.52 but also hit the highest price of $23.40 during that period. The average intraday trading volume for Capricor Therapeutics Inc shares is 1.90 million. The stock is currently trading -8.36% below its 20-day simple moving average (SMA20), while that difference is down -12.71% for SMA50 and it goes to -23.47% lower than SMA200.

Capricor Therapeutics Inc (NASDAQ: CAPR) currently have 45.68M outstanding shares and institutions hold larger chunk of about 38.55% of that.

The stock has a current market capitalization of $436.67M and its 3Y-monthly beta is at 0.79. It has posted earnings per share of -$1.42 in the same period. It has Quick Ratio of 6.55 while making debt-to-equity ratio of 0.04. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CAPR, volatility over the week remained 18.18% while standing at 13.48% over the month.

Stock’s fiscal year EPS is expected to rise by 63.57% while it is estimated to decrease by -3.32% in next year.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Piper Sandler on October 21, 2024 offering an Overweight rating for the stock and assigned a target price of $35 to it. Coverage by Oppenheimer stated Capricor Therapeutics Inc (CAPR) stock as an Outperform in their note to investors on May 17, 2024, suggesting a price target of $14 for the stock. On January 05, 2024, Cantor Fitzgerald Initiated their recommendations, while on October 26, 2022, Ladenburg Thalmann Initiated their ratings for the stock with a price target of $15. Stock get a Hold rating from Maxim Group on December 26, 2018.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.